Executive Leadership

Kasper Møller, Ph.D

Chief Technical Officer and Executive Vice President, Europe & Japan Regions

Kasper Møller was appointed EVP of Europe and Japan regions in 2023, and Chief Technical Officer in June 2019, after serving for two years as General Manager and Site Head for our Copenhagen facility. Throughout his time at AGC Biologics, Kasper has provided expertise in process characterization and validation, in previous roles such as Principal Scientist, Department Manager within Process Development, Vice President of Process Development and Vice President of Manufacturing. Earlier in his career, Kasper spent five years as an assistant professor and faculty member at the Technical University of Denmark, conducting research, and teaching fermentation technology and metabolic engineering.

Kasper earned a Ph.D. in Biochemical Engineering, with a focus on microbial physiology, from the Technical University of Denmark. He pursued his post-doc at the university’s Center for Process Biotechnology, as well as the Department of Genetics at Washington University Medical School in St. Louis. Along the way, he contributed to more than a dozen scientific international journals and publications.

Christoph Winterhalter

Chief Business Officer

Christoph Winterhalter assumed the role of Chief Business Officer in March 2024 and oversees corporate strategy, business development, new business initiatives and global marketing for the AGC Biologics CDMO network. He brings 30 years of experience in the life science, CDMO and biopharmaceutical outsourcing space, and previously served as the Senior Vice President Business Development EMEA for AGC Biologics.

Christoph joined AGC Biologics in 2018 and has contributed significantly to the company’s growth over the past six years. Before AGC Biologics, he most recently served as the Senior Vice President of Global Business Development for the CDMO Rentschler Biopharma. Reporting directly to the CEO, he guided the company’s global sales and development strategy and created strategic manufacturing alliances with leading global biopharmaceutical companies. While there, he was instrumental in tripling the top-line sales numbers for the company. Before that, Christoph worked at Wacker Chemie AG supporting its Life Science businesses for nearly 20 years, most recently serving as Vice President of Biosolutions for the Americas. At Wacker he managed teams focused on Research and Development (R&D), Project Management, GMP Production, Business Development, and Marketing.

Christoph received a degree in Microbiology and his Doctorate from the Technical University of Munich.

Yuichiro “Roy” Tashiro

Executive Vice President, Corporate Functions

Roy was appointed head of the AGC Biologics Legal and People & Culture (P&C) departments in January 2026. He is a seasoned legal and compliance leader with more than two decades of global experience across Japan, the Americas, and Europe, working in the legal department at AGC Inc. and its U.S. subsidiaries. During his career, Roy has led global and regional compliance and trade control teams and programs, helped companies address evolving regulatory requirements, and guided initiatives that minimize risk and create stronger business performance.

He earned a Bachelor of Laws (LL.B.) from Kyushu University and holds a Master of Laws (LL.M.) from Duke University. Roy began his career in logistics and commercial operations, bringing a unique combination of legal expertise, regulatory leadership, and international business knowledge to this role.

Carrie Mygatt

Executive Vice President, Finance

Carrie Mygatt was appointed to the role of EVP Finance at AGC Biologics in October 2023. Carrie brings over 30 years of operational financial leadership experience in finance, accounting, treasury, IT, HR and procurement.   Prior to joining AGC Biologics, Carrie held senior financial positions at Corning, Alvogen, Honeywell and Stryker.

Carrie is a licensed CPA in the state of Missouri and earned a B.S. in Accounting from Southern Illinois University at Carbondale.

Luca Alberici

Executive Vice President, Global Cell & Gene Technologies and General Manager, Milan Facility

Luca Alberici, assumed the role of Executive Vice President of Global Cell and Gene Technologies in February 2025 in addition to being the head of AGC Biologics Milan site. Luca is a value driven professional who came to AGC Biologics through the July 2020 acquisition of MolMed, a leading cell and gene therapy company. His rich educational background is complemented by more than 15 years of industry experience in roles of increasing responsibility for strategic business development and operations, licensing, project management and intellectual property for large molecule and specialty drug development and commercialization. Throughout his career, Luca has been fundamental in licensing and strategic supply agreements that drove top line results in his former position as Chief Business Officer at MolMed. In addition to practical proficiency with discovery and development for HIV and tumor therapies in his early career, Luca has extensive experience in negotiating go-to-market strategies and bringing new cell and gene therapies to market through partnerships with leading biopharmaceutical companies.

Luca earned a PhD and Masters in cellular and molecular biology from Libera Università Vita-Salute San Raffaele, in addition to a Master of Business Administration (MBA) from SDA Bocconi. He has a thorough understanding of European regulatory requirements and pricing policies, and is a published author and frequent industry speaker.

Kohei Yokoyama

Executive Vice President, Region Japan Facilitator

Kohei Yokoyama leads seamless communication and collaboration across the AGC Biologics Japanese sites in Chiba and Yokohama. In this role, he facilitates operations management for Japan region. Kohei also oversees AGC Biologics' Global Engineering and the Enterprise Resource Planning for the company's Chiba, Yokohama and Copenhagen sites.

He is a seasoned technology and business leader, most recently serving as General Manager in the Technology Management Division at AGC Inc., where he focused on advancing innovation and strategic initiatives within the company’s Life Sciences and Materials Development businesses. He retains this position and will focus on enabling strong organization and partnership across the Engineering, IT, Research & Development, and Operational Excellence groups.

With a strong academic foundation from Keio University, Kohei has built his career at AGC Inc. through various roles, in Manufacturing and Engineering across both the Chemicals and Life Science Companies, helping bridge technology, research, and business operations to create sustainable growth.

Martin Shawala

Senior Vice President, Quality

Marty Shawala serves as the Senior Vice President of Quality at AGC Biologics, bringing more than 26 years of experience in pharmaceutical quality and manufacturing leadership.  In this role, Marty is a key member of the Executive Leadership Team, where he is responsible for setting the quality strategy and aligning QA, QC, Quality Systems, Validation, and Regulatory Compliance operations with corporate objectives across all sites and within Global Quality.

Prior to joining AGC Biologics, Marty held different Quality leadership roles at Takeda, Genzyme, Schering-Plough, DEY Laboratories, and Ben Venue Laboratories.  His background allowed him to acquire expertise in aseptic processing, validation, contamination control, and facility start-up operations.  He is proficient in the development and deployment of quality strategy across GXP areas, leading successful FDA and regulatory inspections, and implementing programs that improve employee retention and strengthen quality culture.

Marty holds a Bachelor of Arts and Sciences degree in Biological Sciences from Case Western Reserve University, where he graduated Cum Laude.  He is trained in Lean Six Sigma and is recognized for driving continuous improvement initiatives and global cross-site quality integration efforts that support operational excellence.

Dieter Kramer

Senior Vice President and General Manager, Heidelberg Facility

As the General Manager of the Heidelberg facility, Dieter Kramer applies two decades of technical and leadership expertise. Dieter joined AGC Biologics in July 2018, having worked in a similar role at Corden Biochem GmbH, a full-service Contract Manufacturing Organization. Dieter brings breadth and depth to his role. Combining the disciplines of business and chemical engineering, he held various positions in R&D, manufacturing, project management and general management in the Sandoz/Novartis network in Austria and Germany. In particular, he spent five years as Managing Director of an API manufacturing site with large-scale fermentation and downstream capabilities.

Dieter pursued his education in Austria. He earned a Master of Business Administration from Management Center Innsbruck. He received his master’s degree in Technical Chemistry and Biotechnology at the Technical University of Graz. He completed his education at Höhere Technische Bundeslehranstalt in Wels with advanced study in chemical engineering.

Jun Takami

Senior Vice President and General Manager, Japan Region & Yokohama Facility

Jun Takami, General Manager of AGC Biologics’ Japan Region, joined AGC Inc. in September 2017. He brings over 15 years of experience in the pharmaceutical industry, with roles in process development, GMP manufacturing, process engineering, team management and PLI activities at Chugai Pharmaceutical within Roche Group.

After joining AGC Inc., he helped design and introduce mammalian capacity of both 500 L and 2,000 L scale at the Chiba site. He was appointed as Project Management Director, a role which he held for two years. In parallel, he supported business development activities by bringing customers to the Chiba site. For more than three years, he led the Chiba site operations in executing both microbial and mammalian projects for our global customers. Starting in 2024 Jun brought his considerable expertise to a new role as General Manager of the Japan region and the operational readiness of the the Yokohama site. Jun has experience cultivating strong leadership teams, each dedicated to the success of development, manufacturing, supply chain, engineering and quality. He also works to keep our quality culture top-of-mind within AGC.

Jun holds a Masters in biological science from Kobe University, as well as Bachelor’s degree.

Ketan Amin

Senior Vice President and General Manager, Seattle Facility

Ketan Amin, Interim General Manager and VP of MSAT and Process Development for the Seattle, Washington, facility, joined AGC Biologics in 2023. He has over 25 years of pharmaceutical experience, including 19 years at Johnson & Johnson, where he served in various leadership roles overseeing global biologics development, including drug product, device, formulation, validation, manufacturing, clinical trials, commercialization, and supply chain. 

Ketan brings hands-on expertise and insights to AGC Biologics' Seattle site through his experience both as a pharmacist as well as his many different roles in drug development and formulation.

Ketan earned a Bachelor's of Pharmaceutical Sciences from the North Carolina School of Pharmacy and a PhD from the University of Wisconsin.  Afterward, he went on to receive an MBA from the Northwestern Kellogg School of Management. 

Susumu Zen-in

Senior Vice President and General Manager, Chiba Facility

Susumu Zenin, the General Manager of AGC Biologics Chiba facility, joined AGC Inc. in December 2015. Since then, he has played an important role in manufacturing and process development and has held a variety of positions including 5 years as a manager and director of microbial manufacturing, as well as 3 years leading a process development team as a Sr. Director. With over 15 years of experience in the pharmaceutical industry, and expertise in not only GMP manufacturing, process development, and R&D but also quality assurance at AGC and Japanese biotech JCR Pharmaceuticals Co., Ltd, Susumu brings a wide breadth of knowledge and skills to our Chiba team.

Susumu holds a Master of Bioscience from Hokkaido University, as well as a Bachelor's degree.